PTPRD

Summary

PTPRD (protein tyrosine phosphatase receptor type D, HGNC:9668) is a protein-coding gene on chromosome 9p24.1-p23, encoding Receptor-type tyrosine-protein phosphatase delta (P23468). Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. In precision oncology, PTPRD V253I confers sensitivity to Cixutumumab + Teprotumumab in Ewing Sarcoma Of Bone (CIViC Level C); 1 further curated variant–drug associations are listed below.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular region, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region of this protein is composed of three Ig-like and eight fibronectin type III-like domains. Studies of the similar genes in chicken and fly suggest the role of this PTP is in promoting neurite growth, and regulating neurons axon guidance. Multiple alternatively spliced transcript variants of this gene have been reported. A related pseudogene has been identified on chromosome 5.

Source: NCBI Gene 5789 — RefSeq curated summary.

At a glance

• GWAS associations: 103
• Clinical variants (ClinVar): 344 total
• Druggable target: yes
• Precision-oncology evidence (CIViC): 2 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 11 cancer types
• MANE Select transcript: NM_002839

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9668
Approved symbol	PTPRD
Name	protein tyrosine phosphatase receptor type D
Location	9p24.1-p23
Locus type	gene with protein product
Status	Approved
Aliases	PTPD, HPTP
Ensembl gene	ENSG00000153707
Ensembl biotype	protein_coding
OMIM	601598
Entrez	5789

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 16 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000355233, ENST00000356435, ENST00000381196, ENST00000397606, ENST00000397611, ENST00000397617, ENST00000463477, ENST00000471274, ENST00000477552, ENST00000481079, ENST00000486161, ENST00000488774, ENST00000537002, ENST00000540109, ENST00000637354, ENST00000651105, ENST00000850942, ENST00000855711, ENST00000855712, ENST00000855713

RefSeq mRNA: 10 — MANE Select: NM_002839 NM_001040712, NM_001171025, NM_001377946, NM_001377947, NM_001377958, NM_001378058, NM_002839, NM_130391, NM_130392, NM_130393

CCDS: CCDS43786, CCDS55288, CCDS55289, CCDS55290, CCDS6472, CCDS75813

Canonical transcript exons

ENST00000381196 — 46 exons

Exon	Start	End
ENSE00001012014	8484119	8484378
ENSE00001012016	8485762	8486349
ENSE00001012020	8517848	8518429
ENSE00001012021	8340343	8340469
ENSE00001012025	8319831	8319966
ENSE00001012031	8376607	8376726
ENSE00001012032	8404537	8404660
ENSE00001012033	8485227	8485324
ENSE00001012034	8375936	8376090
ENSE00001012036	8465466	8465675
ENSE00001012037	8460411	8460571
ENSE00001087338	8521277	8521546
ENSE00001087346	8524925	8525035
ENSE00001172611	8341090	8341268
ENSE00001172619	8341693	8341978
ENSE00001172638	8389232	8389407
ENSE00001172655	8436592	8436689
ENSE00001172661	8449725	8449837
ENSE00001172680	8470995	8471085
ENSE00001172700	8497242	8497268
ENSE00001172713	8507301	8507434
ENSE00001172741	8633317	8633458
ENSE00001172744	8636699	8636844
ENSE00001254378	8314246	8317942
ENSE00001254389	8733780	8733946
ENSE00001368106	8504261	8504405
ENSE00001487965	9018697	9018735
ENSE00001656481	8338922	8339047
ENSE00001662513	8523513	8523524
ENSE00001707976	8331582	8331736
ENSE00001739974	8526627	8526644
ENSE00001780939	8527345	8527353
ENSE00001811856	9938507	9938610
ENSE00001817715	9397449	9397482
ENSE00001824156	10612398	10612505
ENSE00001845659	10340963	10341017
ENSE00001889688	9574732	9574781
ENSE00001895238	10033718	10033790
ENSE00001940698	9183304	9183363
ENSE00001948254	9766810	9766851
ENSE00001955782	9734533	9734571
ENSE00003493095	8492862	8492979
ENSE00003493546	8499647	8499840
ENSE00003574327	8500754	8501059
ENSE00003587167	8528591	8528779
ENSE00003918538	10612688	10613002

Expression profiles

Bgee: expression breadth ubiquitous, 160 present calls, max score 98.01.

FANTOM5 (CAGE): breadth broad, TPM avg 10.4029 / max 754.3581, expressed in 721 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99887	3.3902	564
99918	1.4002	169
99910	0.8973	129
99911	0.5749	106
99893	0.5737	271
99919	0.5287	130
99890	0.4346	145
99914	0.4213	96
99892	0.4112	153
99913	0.3278	71

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.01	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.89	gold quality
cerebellar hemisphere	UBERON:0002245	94.01	gold quality
cerebellar cortex	UBERON:0002129	93.90	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.55	gold quality
ganglionic eminence	UBERON:0004023	93.29	gold quality
adrenal tissue	UBERON:0018303	91.47	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.27	gold quality
prefrontal cortex	UBERON:0000451	90.65	gold quality
cerebellum	UBERON:0002037	90.31	gold quality
right frontal lobe	UBERON:0002810	89.12	gold quality
spinal cord	UBERON:0002240	88.78	gold quality
anterior cingulate cortex	UBERON:0009835	86.98	gold quality
descending thoracic aorta	UBERON:0002345	85.19	gold quality
rectum	UBERON:0001052	84.98	gold quality
hypothalamus	UBERON:0001898	84.88	gold quality
stromal cell of endometrium	CL:0002255	84.41	gold quality
right ovary	UBERON:0002118	84.02	gold quality
amygdala	UBERON:0001876	83.99	gold quality
left ovary	UBERON:0002119	83.89	gold quality
putamen	UBERON:0001874	83.51	gold quality
caudate nucleus	UBERON:0001873	83.08	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.59	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.51	gold quality
thoracic aorta	UBERON:0001515	82.37	gold quality
ascending aorta	UBERON:0001496	82.06	gold quality
neocortex	UBERON:0001950	81.89	gold quality
calcaneal tendon	UBERON:0003701	81.38	gold quality
colonic epithelium	UBERON:0000397	81.35	gold quality
frontal cortex	UBERON:0001870	81.30	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	68.80
E-CURD-119	yes	49.04
E-GEOD-93593	yes	10.47
E-ANND-3	yes	8.07
E-HCAD-25	no	6399.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

351 targeting PTPRD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784

Literature-anchored findings (GeneRIF, showing 40)

• interactions between RPTP-domain1s and RPTP-domain 2s are a common but specific mechanism that is likely to be regulated- domain2s and the wedge structures are crucial determinants of binding specificity, thus regulating cross-talk between RPTPs (PMID:12376545)
• A novel isoform of PTPRD was cloned and its expression analyzed. (PMID:16114034)
• data identify PTPRD as a candidate tumor suppressor gene in cutaneous squamous cell carcinoma with a possible association with metastasis (PMID:17420988)
• The aberrant splicing or microdeletion of 5’ UTR exons in such a high proportion of tumors indicates that loss of these exons dys-regulates the mRNA sequence (PMID:18050303)
• The results indicate that polymorphisms of PTPRD are strongly associated with pediatric bronchial asthma in the Taiwanese population. (PMID:18414509)
• Two independent SNPs in the 5’ UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values, identifying PTPRD as the fourth genome-wide significant locus for restless legs syndrome. (PMID:18660810)
• These results implicate PTPRD as a tumor suppressor on chromosome 9p that is involved in the development of glioblastoma multiforme and multiple human cancers. (PMID:19478061)
• No mutations of PTPRD were associated with familiar melanoma (PMID:19500277)
• Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study (PMID:19525478)
• Results found the PTPRD gene was most frequently homozygously deleted gene in human lung cancer among genes mapping to regions other than 9p21. (PMID:20073072)
• Trans-synaptic adhesions between netrin-G ligand-3 (NGL-3) and receptor tyrosine phosphatases LAR, protein-tyrosine phosphatase delta (PTPdelta), and PTPsigma via specific domains regulate excitatory synapse formation. (PMID:20139422)
• statistical significant downregulation of PCDH17/PCH68 and PTPRD was observed (PMID:21213369)
• Both family-based and population-based association studies suggest that PTPRD variant rs1975197 confers risk of RLS. (PMID:21264940)
• Eight suggestive significant loci were detected with a series of genes expressed within the inner ear that underlie the auditory function, such as: DCLK1, PTPRD, GRM8, CMIP. (PMID:21493956)
• Data indicate that genetic variants near the KCNQ1 and MAF/WWOX genes are associated with reduced insulin secretion, and the PTPRD genetic variant appears to be associated with progression to diabetes in Han Chinese. (PMID:21767287)
• The interaction of the IL1RAPL1 family of proteins with PTPdelta and RhoGAP2 reveals a pathophysiological mechanism of cognitive impairment associated with a novel type of trans-synaptic signaling. (PMID:21926414)
• This is the first report to observe an association between deletion within PTPRD and metastatic cutaneous squamous cell carcinoma. (PMID:22052591)
• PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the function of PTPRD in neuroblastoma. (PMID:22305495)
• Although endogenous PTPdelta expression was very low in neuroblastoma cells, it was also low in mouse embryo adrenal glands, suggesting that PTPdelta may have little developmental function in early adrenal neuroblasts. (PMID:22571343)
• Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma. (PMID:23069849)
• Diabetes risk alleles in PPARG2(rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. (PMID:23147557)
• Loss of PTPRD gene is associated with squamous cell carcinomas of the vulva. (PMID:23404381)
• Data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma. (PMID:23800680)
• Data indicate that expression of several predicted chimeric genes and genes with disrupted exon structure including ALK, NBAS, FHIT, PTPRD and ODZ4 in neuroblastoma. (PMID:23991058)
• We reveal that PTPRD is a bona fide tumor suppressor, pinpoint PTPRD loss as a cause of aberrant STAT3 activation in gliomas, and establish PTPRD loss, in the setting of CDKN2A/p16(INK4A) deletion, as a driver of glioma progression. (PMID:24843164)
• we report desmoplakin, a desmosomal protein that is implicated in cell-cell adhesion, as a novel PTPRD substrate. (PMID:25113440)
• Ptprd is a tumor suppressor that can promote tumorigenesis in concert with Cdkn2a loss. (PMID:25138050)
• Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD (PMID:25142570)
• The absence of MIM led to PTPdelta-mediated activation of SRC. (PMID:25287652)
• This study demonstrated that the copy number variations of PTPRD relate to opioid dependence. (PMID:25345593)
• Silencing PTPRD expression by siRNA treatment significantly enhanced cell proliferation compared with mock siRNA treatment. (PMID:25412184)
• PTPRD is homozygously deleted and epigenetically downregulated in hepatocellular carcinomas (HCCs). (PMID:25831062)
• Study shows for the first time that DNMT1 caused PTPRD DNA hypermethylation and induced insulin signaling silencing in T2D patients. (PMID:26079428)
• PTPRD mutation, but not methylation or copy number loss, may serve as a predictive biomarker of sensitivity to STAT3 inhibitors in HNSCC. (PMID:26267899)
• PTPRD was identified as a novel locus potentially associated with blood pressure response to atenolol and resistant hypertension in multiple ethnic groups. (PMID:26425837)
• overexpression in acute myeloid leukaemia cells inhibited cell proliferation and clonogenicity as well as inducing apoptosis (PMID:26607758)
• PTPRD polymorphisms might modulate antipsychotic-induced weight gain. (PMID:26656879)
• We investigated the modification of air pollution and diabetes association by a genetic risk score covering 63 T2D genes. Five single variants near GRB14, UBE2E2, PTPRD, VPS26A and KCNQ1 showed nominally significant interactions with PM10 (P<0.05). Our results suggest that genetic risk for T2D may modify susceptibility to air pollution through alterations in insulin sensitivity (PMID:27281273)
• Mutation in PTPRD gene is associated with nodal marginal zone lymphoma. (PMID:27335277)
• Low PTPRD expression is associated with Head and Neck Squamous Cell Carcinoma. (PMID:27501229)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptprdb	ENSDARG00000019945
		ENSDARG00000104937
mus_musculus	Ptprd	ENSMUSG00000028399
rattus_norvegicus	Ptprd	ENSRNOG00000005711

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase delta — P23468 (reviewed: P23468)

All UniProt accessions (6): P23468, A0A1B0GU15, C9J6E4, C9J8S8, F5GWR7, Q3KPI9

UniProt curated annotations — full annotation on UniProt →

Function. Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.

Subunit / interactions. Interacts with PPFIA1, PPFIA2 and PPFIA3. Interacts (via extracellular domain) with SLITRK4 (via LRR 1 and 2 repeats). Interacts with SLITRK2; induces presynaptic differentiation. Interacts (via the second immunoglobilin domain) with IL1RAPL1 (via the first immunoglobilin domain); induces pre- and postsynaptic differentiation of neurons and synapse formation. Interacts (via the third immunoglobilin domain) with IL1RAP (via the first immunoglobilin domain); induces pre- and postsynaptic differentiation of neurons.

Subcellular location. Membrane.

Post-translational modifications. A cleavage occurs, separating the extracellular domain from the transmembrane segment. This process called ’ectodomain shedding’ is thought to be involved in receptor desensitization, signal transduction and/or membrane localization.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 2A subfamily.

Isoforms (7)

UniProt ID	Names	Canonical?
P23468-1	1	yes
P23468-2	2, Kidney
P23468-3	3, Fetal brain
P23468-4	4
P23468-5	5
P23468-6	6
P23468-7	7

RefSeq proteins (10): NP_001035802, NP_001164496, NP_001364875, NP_001364876, NP_001364887, NP_001364987, NP_002830, NP_569075, NP_569076, NP_569077 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR045905	R-PTP-delta_cat	Domain
IPR050713	RTP_Phos/Ushers	Family

Pfam: PF00041, PF00102, PF07679, PF13927

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (134 total): strand 65, domain 13, splice variant 13, helix 7, sequence variant 6, region of interest 5, turn 4, glycosylation site 4, binding site 3, disulfide bond 3, topological domain 2, active site 2, site 2, mutagenesis site 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
2YD6	X-RAY DIFFRACTION	1.35
6X3A	X-RAY DIFFRACTION	1.77
2YD7	X-RAY DIFFRACTION	1.98
4RCA	X-RAY DIFFRACTION	2.99
5WY8	X-RAY DIFFRACTION	3.07
5XNP	X-RAY DIFFRACTION	3.73
1X5Z	SOLUTION NMR
2DLH	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23468-F1	83.02	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 1553 (phosphocysteine intermediate); 1844 (phosphocysteine intermediate); 266 (required for interaction with il1rap); 1181–1182 (cleavage)

Ligand- & substrate-binding residues (3): 1521; 1553–1559; 1597

Disulfide bonds (3): 45–98, 147–207, 257–302

Glycosylation sites (4): 254, 299, 724, 832

Mutagenesis-validated functional residues (2):

Position	Phenotype
1178	2.5-fold reduction in cleavage. 10-fold reduction in cleavage; when associated with a-1181.
1181	no reduction in cleavage. 10-fold reduction in cleavage; when associated with a-1178.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-8849932	Synaptic adhesion-like molecules

MSigDB gene sets: 357 (showing top): GOBP_DENDRITE_DEVELOPMENT, GCM_MAP4K4, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GCM_PTPRD, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_SYNAPSE_ASSEMBLY, GOBP_MEMBRANE_BIOGENESIS, MODULE_64, GOBP_REGULATION_OF_DENDRITE_MORPHOGENESIS, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT

GO Biological Process (20): phosphate-containing compound metabolic process (GO:0006796), heterophilic cell-cell adhesion (GO:0007157), signal transduction (GO:0007165), cell surface receptor protein tyrosine phosphatase signaling pathway (GO:0007185), nervous system development (GO:0007399), neuron differentiation (GO:0030182), negative regulation of receptor signaling pathway via JAK-STAT (GO:0046426), regulation of immune response (GO:0050776), modulation of chemical synaptic transmission (GO:0050804), positive regulation of synapse assembly (GO:0051965), positive regulation of dendritic spine morphogenesis (GO:0061003), presynaptic membrane assembly (GO:0097105), presynapse assembly (GO:0099054), regulation of postsynaptic density assembly (GO:0099151), trans-synaptic signaling by trans-synaptic complex (GO:0099545), synaptic membrane adhesion (GO:0099560), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311), positive regulation of dendrite morphogenesis (GO:0050775), trans-synaptic signaling (GO:0099537)

GO Molecular Function (7): protein tyrosine phosphatase activity (GO:0004725), transmembrane receptor protein tyrosine phosphatase activity (GO:0005001), signaling receptor binding (GO:0005102), cell adhesion molecule binding (GO:0050839), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (7): plasma membrane (GO:0005886), presynaptic membrane (GO:0042734), extracellular exosome (GO:0070062), Schaffer collateral - CA1 synapse (GO:0098685), hippocampal mossy fiber to CA3 synapse (GO:0098686), glutamatergic synapse (GO:0098978), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Protein-protein interactions at synapses	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	2
synapse assembly	2
protein binding	2
synapse	2
metabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
system development	1
cell differentiation	1
generation of neurons	1
cell surface receptor signaling pathway via JAK-STAT	1
regulation of receptor signaling pathway via JAK-STAT	1
negative regulation of receptor signaling pathway via STAT	1
regulation of immune system process	1
immune response	1
regulation of response to stimulus	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
positive regulation of neuron projection development	1
positive regulation of dendrite morphogenesis	1
dendritic spine morphogenesis	1
positive regulation of dendritic spine development	1
regulation of dendritic spine morphogenesis	1
membrane assembly	1
presynaptic membrane organization	1
presynapse assembly	1
cellular component assembly	1
presynapse organization	1
postsynaptic density assembly	1
regulation of postsynaptic specialization assembly	1
regulation of excitatory synapse assembly	1
regulation of postsynaptic density organization	1
trans-synaptic signaling	1

Protein interactions and networks

STRING

2772 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRD	PPFIA1	Q13136	901
PTPRD	SLITRK3	O94933	858
PTPRD	IL1RAPL1	Q9NZN1	751
PTPRD	BTBD9	Q96Q07	727
PTPRD	LRP1B	Q9NZR2	727
PTPRD	PPFIBP1	Q86W92	662
PTPRD	PPFIBP2	Q8ND30	642
PTPRD	SLITRK1	Q96PX8	626
PTPRD	MTSS1	O43312	611
PTPRD	PPFIA3	O75145	604
PTPRD	SLITRK2	Q9H156	589
PTPRD	PTS	Q03393	583
PTPRD	AUTS2	Q8WXX7	563
PTPRD	IL1RAP	Q9NPH3	555
PTPRD	MAP2K5	Q13163	553

IntAct

119 interactions, top by confidence:

A	B	Type	Score
EGFR	CTNND1	psi-mi:“MI:0914”(association)	0.750
NIPAL1	ESYT2	psi-mi:“MI:0914”(association)	0.640
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
EGFR	PTPRD	psi-mi:“MI:0915”(physical association)	0.550
PTPRD	AURKA	psi-mi:“MI:0915”(physical association)	0.540
PTPRD	AURKA	psi-mi:“MI:0407”(direct interaction)	0.540
LRFN4	PTPRD	psi-mi:“MI:0915”(physical association)	0.540
PTPRD	LRFN1	psi-mi:“MI:0915”(physical association)	0.540
LRFN5	PTPRD	psi-mi:“MI:0915”(physical association)	0.540
LRFN1	PTPRD	psi-mi:“MI:0407”(direct interaction)	0.540
PTPRD	LRFN4	psi-mi:“MI:0407”(direct interaction)	0.540
LRFN5	PTPRD	psi-mi:“MI:0407”(direct interaction)	0.540
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
PCDHB16	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
LINGO2	GAPDHS	psi-mi:“MI:0914”(association)	0.530
IZUMO1	ADCY3	psi-mi:“MI:0914”(association)	0.530
MRAP2	PODXL	psi-mi:“MI:0914”(association)	0.530
PTPRD	SLAIN2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	NEK1	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	PLK1	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	EPHA8	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	TBK1	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	CSNK1D	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	CSNK1E	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	MARK2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	TSSK2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	SMTNL2	psi-mi:“MI:0407”(direct interaction)	0.440
PTPRD	PAK6	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (161): PTPRD (Affinity Capture-MS), PTPRD (Affinity Capture-MS), PTPRD (Affinity Capture-MS), PTPRD (Affinity Capture-MS), PPFIA1 (Two-hybrid), PPFIA2 (Two-hybrid), PPFIA3 (Two-hybrid), PTPRD (Affinity Capture-MS), COPG2 (Affinity Capture-MS), HADHA (Affinity Capture-MS), HADHB (Affinity Capture-MS), TPP2 (Affinity Capture-MS), DSC3 (Proximity Label-MS), TRIO (Proximity Label-MS), PTPRD (Affinity Capture-MS)

ESM2 similar proteins: A2A8L5, A4IFW2, A7MBJ4, B0V2N1, F1NWE3, O00533, O42414, O55005, O89026, O94856, O97394, P10586, P11627, P16621, P22063, P23468, P28685, P32004, P70232, P97685, P97686, Q02246, Q05695, Q13332, Q28902, Q2EY14, Q2EY15, Q2VWP7, Q2VWP9, Q3UH53, Q589G5, Q58EX2, Q61330, Q64487, Q64604, Q64605, Q6V4S5, Q7Z5N4, Q810U3, Q810U4

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
PTPRD	down-regulates	STAT3	dephosphorylation
PTPRD	“down-regulates activity”	STAT3	dephosphorylation
LRFN5	“up-regulates activity”	PTPRD	binding
PTPRD	up-regulates	Synaptic_plasticity

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 150 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Synaptic adhesion-like molecules	6	33.3×	1e-05
Protein-protein interactions at synapses	6	16.3×	4e-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	7	6.9×	7e-03
PIP3 activates AKT signaling	9	6.1×	3e-03
Neuronal System	13	5.9×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
synaptic membrane adhesion	7	31.3×	2e-06
regulation of presynapse assembly	6	25.1×	7e-05
regulation of heart rate by cardiac conduction	5	14.4×	7e-03
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	6	9.7×	8e-03
protein phosphorylation	11	5.8×	1e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 11 cancer types — BRCA, EGC, ESCA, ESCC, LNM, MEL, NHL, OVT, PAAD, SIC, SKCM.

Clinical variants and AI predictions

ClinVar

344 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	222
Likely benign	39
Benign	25

Top pathogenic / likely-pathogenic (0)

SpliceAI

10455 predictions. Top by Δscore:

Variant	Effect	Δscore
9:8331577:CTTA:C	donor_loss	1.0000
9:8331578:TTACC:T	donor_loss	1.0000
9:8331579:TA:T	donor_loss	1.0000
9:8331580:A:AC	donor_gain	1.0000
9:8331580:A:C	donor_loss	1.0000
9:8331581:C:CC	donor_gain	1.0000
9:8331581:CCTG:C	donor_gain	1.0000
9:8331790:A:T	acceptor_gain	1.0000
9:8331817:C:CT	acceptor_gain	1.0000
9:8331820:T:C	acceptor_gain	1.0000
9:8331830:C:CT	acceptor_gain	1.0000
9:8331830:C:T	acceptor_gain	1.0000
9:8331831:G:T	acceptor_gain	1.0000
9:8338917:CTTA:C	donor_loss	1.0000
9:8338918:TTA:T	donor_loss	1.0000
9:8338919:TA:T	donor_loss	1.0000
9:8338920:A:AC	donor_gain	1.0000
9:8338920:A:AG	donor_loss	1.0000
9:8338920:AC:A	donor_gain	1.0000
9:8338920:ACC:A	donor_gain	1.0000
9:8338921:C:A	donor_loss	1.0000
9:8338921:C:CC	donor_gain	1.0000
9:8338921:CC:C	donor_gain	1.0000
9:8338921:CCC:C	donor_gain	1.0000
9:8338921:CCCT:C	donor_gain	1.0000
9:8339043:TTCTC:T	acceptor_gain	1.0000
9:8339045:CTC:C	acceptor_gain	1.0000
9:8339046:TC:T	acceptor_gain	1.0000
9:8339047:CC:C	acceptor_gain	1.0000
9:8339047:CCT:C	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000000359 (9:9680733 T>A), RS1000000705 (9:9156025 T>C), RS1000000980 (9:10172609 T>C), RS1000003375 (9:10353163 A>G), RS1000004128 (9:9939574 C>A,T), RS1000008944 (9:8827714 T>C), RS1000010052 (9:8942415 A>C,G), RS1000010181 (9:10529937 G>A), RS1000010816 (9:8689867 G>A), RS1000010966 (9:9159306 G>A), RS1000011611 (9:8661475 A>C), RS1000012064 (9:9453328 A>G), RS1000012602 (9:8373736 G>A), RS1000013584 (9:9565128 T>C), RS1000014625 (9:8699001 C>T)

Disease associations

OMIM: gene MIM:601598 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

103 associations (top):

Study	Trait	p-value
GCST000214_1	Restless legs syndrome	6.000000e-09
GCST000214_2	Restless legs syndrome	6.000000e-10
GCST000253_19	Attention deficit hyperactivity disorder and conduct disorder	6.000000e-06
GCST000601_1	Type 2 diabetes	9.000000e-10
GCST000691_4	Partial epilepsies	9.000000e-06
GCST000693_10	Platelet aggregation	1.000000e-07
GCST001092_1	Type 2 diabetes	6.000000e-06
GCST001159_3	Restless legs syndrome	3.000000e-10
GCST001356_1	Gout	1.000000e-07
GCST001531_12	Temperament	5.000000e-06
GCST001621_3	Airflow obstruction	1.000000e-06
GCST001712_36	Myopia (pathological)	9.000000e-07
GCST001762_745	Obesity-related traits	7.000000e-06
GCST001838_6	Palmitic acid (16:0) levels	9.000000e-07
GCST002111_2	Personality dimensions	3.000000e-08
GCST002141_6	Epilepsy (remission after treatment)	3.000000e-07
GCST002200_2	Anxiety and major depressive disorder	2.000000e-06
GCST002358_11	Pit-and-Fissure caries	4.000000e-06
GCST002441_8	Immune response to measles-mumps-rubella vaccine	3.000000e-10
GCST002451_1	Obsessive-compulsive disorder	4.000000e-07
GCST002541_71	Menarche (age at onset)	1.000000e-07
GCST003054_2	Gait rhythm	8.000000e-07
GCST003133_10	Plasma clusterin levels	5.000000e-06
GCST003170_4	Subcutaneous adipose tissue	7.000000e-07
GCST003225_31	Pelvic organ prolapse (moderate/severe)	9.000000e-07
GCST003245_2	White matter hyperintensities in ischemic stroke	3.000000e-07
GCST003262_576	Post bronchodilator FEV1	5.000000e-07
GCST003263_3	Post bronchodilator FEV1 in COPD	2.000000e-06
GCST003263_4	Post bronchodilator FEV1 in COPD	4.000000e-06
GCST003264_1082	Post bronchodilator FEV1/FVC ratio	4.000000e-06

EFO canonical traits (54, from GWAS)

EFO ID	Trait name
EFO:0004825	temperament and character inventory
EFO:0003892	pulmonary function measurement
EFO:0004207	pathological myopia
EFO:0003939	energy intake
EFO:0004365	personality trait
EFO:0004645	response to vaccine
EFO:0004703	age at menarche
EFO:0007656	plasma clusterin measurement
EFO:0005665	white matter hyperintensity measurement
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0007865	loneliness measurement
EFO:0004763	p-tau measurement
EFO:0005937	longitudinal BMI measurement
EFO:0007042	polychlorinated biphenyls measurement
EFO:0007959	fetal genotype effect measurement
EFO:0007964	gestational serum measurement
EFO:0007970	estrone measurement
EFO:0007972	androstenedione measurement
EFO:0008433	pursuit maintenance gain measurement
EFO:0008475	mood instability measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008343	sex interaction measurement
EFO:0004357	electroencephalogram measurement
EFO:0006335	systolic blood pressure
EFO:0006336	diastolic blood pressure
EFO:0009270	heel bone mineral density
EFO:0005763	pulse pressure measurement
EFO:1002006	treatment-resistant hypertension
EFO:0004335	short-term memory

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196075 (SINGLE PROTEIN)

Clinical evidence (CIViC)

Drug × variant × indication: 2 predictive associations from 2 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
PTPRD V253I	Cixutumumab + Teprotumumab	Ewing Sarcoma Of Bone	Sensitivity/Response	CIViC C	EID1856
PTPRD Mutation	JSI-124	Head And Neck Carcinoma	Sensitivity/Response	CIViC D	EID807

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

3 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs17584499	Efficacy	3	pioglitazone	Diabetes Mellitus;Type 2
rs324498	Efficacy	3	Antihypertensives	Hypertension
rs4742610	Efficacy	3	trandolapril;verapamil	Hypertension

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4742610	PTPRD	3	1.75	1	trandolapril;verapamil
rs17584499	PTPRD	3	2.25	1	pioglitazone
rs324498	PTPRD	3	0.00	1	Antihypertensives

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
7-BIA	Inhibition	6.0	pIC50

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation	5
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
trichostatin A	affects cotreatment, decreases expression	2
sodium arsenite	affects methylation, increases expression	2
Nickel	decreases expression	2
Aflatoxin B1	decreases methylation, affects expression	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
testosterone enanthate	affects expression	1
methyleugenol	decreases expression	1
bisphenol A	increases methylation	1
senecionine	decreases expression	1
senkirkine	decreases expression	1
heliotrine	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
incobotulinumtoxinA	decreases expression	1
NSC 689534	increases expression	1
Irinotecan	increases expression	1
Temozolomide	decreases expression	1
Vorinostat	decreases expression	1
Air Pollutants	affects response to substance, increases abundance	1
Calcitriol	decreases expression	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6139625	Binding	Inhibition of His-tagged PTP-delta (unknown origin) extracted from Escherichia coli BL21 using pNPP as substrate incubated for 80 mins by spectrophotometric analysis	Discovery and Evaluation of Active Site-Directed, Potent, and Selective Sulfophenyl Acetic Amide-Based Inhibitors for the Laforin Phosphatase. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TH66	HAP1 PTPRD (-) 1	Cancer cell line	Male
CVCL_XS03	HAP1 PTPRD (-) 2	Cancer cell line	Male
CVCL_YD33	SNU-2641	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer